Array
(
[1566547952] => Array
(
[wordfence_hourly_cron] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1566548708] => Array
(
[wordfence_processAttackData] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] =>
[args] => Array
(
)
)
)
)
[1566549573] => Array
(
[wp_privacy_delete_old_export_files] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1566550081] => Array
(
[wpm_update_stats] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1566550171] => Array
(
[wp_scheduled_auto_draft_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1566555311] => Array
(
[delete_expired_transients] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1566555352] => Array
(
[wpseo-reindex-links] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1566562352] => Array
(
[wordfence_daily_cron] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1566567126] => Array
(
[wp_update_themes] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
[wp_version_check] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
[wp_update_plugins] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1566567874] => Array
(
[wp_scheduled_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1566573473] => Array
(
[wp_session_garbage_collection] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1566576424] => Array
(
[akismet_scheduled_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1566579411] => Array
(
[yoast_tracking] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1566630512] => Array
(
[ai1wm_storage_cleanup] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1566828000] => Array
(
[wordfence_email_activity_report] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] =>
[args] => Array
(
)
)
)
)
[1568066453] => Array
(
[publish_future_post] => Array
(
[8e888ca9d0f1614d2214056c615e8cdb] => Array
(
[schedule] =>
[args] => Array
(
[0] => 457438
)
)
)
)
[1569362425] => Array
(
[publish_future_post] => Array
(
[6c2e8ec23ac9ad461e173651b5bf0c29] => Array
(
[schedule] =>
[args] => Array
(
[0] => 439567
)
)
)
)
[1569362446] => Array
(
[publish_future_post] => Array
(
[3139b3d670d2f3719b91143334fe5bbc] => Array
(
[schedule] =>
[args] => Array
(
[0] => 448864
)
)
)
)
[1569448832] => Array
(
[publish_future_post] => Array
(
[4a517b3a869bc596a52baac19dc2a199] => Array
(
[schedule] =>
[args] => Array
(
[0] => 451706
)
)
)
)
[1570399219] => Array
(
[publish_future_post] => Array
(
[4d02969bfd6f2f7ea790268914180d79] => Array
(
[schedule] =>
[args] => Array
(
[0] => 454872
)
)
)
)
[1571954407] => Array
(
[publish_future_post] => Array
(
[7acc756fe0aa0425aac8ad6c3c8dd6e5] => Array
(
[schedule] =>
[args] => Array
(
[0] => 455211
)
)
)
)
[1572390044] => Array
(
[publish_future_post] => Array
(
[0705376047b3e0db33477870d1a7d2d3] => Array
(
[schedule] =>
[args] => Array
(
[0] => 457443
)
)
)
)
[1574550046] => Array
(
[publish_future_post] => Array
(
[892de8dabd22f7830c930f8117a13574] => Array
(
[schedule] =>
[args] => Array
(
[0] => 454502
)
)
)
)
[1580169600] => Array
(
[publish_future_post] => Array
(
[2d492587fa52e9c78f7043ddf937b0a1] => Array
(
[schedule] =>
[args] => Array
(
[0] => 18611
)
)
[dea3edad73162f380bc9dc44fa3407bf] => Array
(
[schedule] =>
[args] => Array
(
[0] => 19670
)
)
[2caa9c58a241c4f77a6856802c1b43fb] => Array
(
[schedule] =>
[args] => Array
(
[0] => 20734
)
)
[307b37ba29b8cd716eafa809661756e3] => Array
(
[schedule] =>
[args] => Array
(
[0] => 22852
)
)
[365be9eba8e62abb0c0d4bfe013a2687] => Array
(
[schedule] =>
[args] => Array
(
[0] => 23918
)
)
[0e942b20ffb9550322105263ad82126f] => Array
(
[schedule] =>
[args] => Array
(
[0] => 24977
)
)
[661c5eb39689fe2133ff7986ac6628fb] => Array
(
[schedule] =>
[args] => Array
(
[0] => 26036
)
)
[75562b264e355915e4dea97042a28f7e] => Array
(
[schedule] =>
[args] => Array
(
[0] => 27095
)
)
[11cf4e8a6f842b0115881551a29c47f6] => Array
(
[schedule] =>
[args] => Array
(
[0] => 28154
)
)
[55a38aaca11da398c854cb29a7d4f5e6] => Array
(
[schedule] =>
[args] => Array
(
[0] => 30272
)
)
[f8cbc904676c235c7057ec965c01c023] => Array
(
[schedule] =>
[args] => Array
(
[0] => 32390
)
)
)
)
[1583794819] => Array
(
[publish_future_post] => Array
(
[9d993985746691420cd7524448c48a23] => Array
(
[schedule] =>
[args] => Array
(
[0] => 448880
)
)
)
)
)
Etiquetas: Abril 2011, AEMPS, Agencia española de medicamentos y productos sanitarios, Atomoxetina, Cambios de especial interés sanitario en medicamentos ya autorizados, Cosméticos, Domperidona, Erbitux, Herceptin, Información sobre seguridad, Informe mensual, Informe mensual sobre medicamentos de uso humano y productos sanitarios, Madrid, medicamentos, Medicamentos de uso humano, Noviembre 2011, Nuevos medicamentos, Otra información de interés, Productos de higiene personal, Productos sanitarios, Rebif, salud, Sanidad, Uso humano.
Etiquetas: 12 diciembre 2011, 12/12/2012, AEMPS, Agencia española de medicamentos y productos sanitarios, Atomoxetina, Cambios de especial interés sanitario en medicamentos ya autorizados, Cosméticos, Domperidona, Erbitux, Herceptin, Información sobre seguridad, Informe mensual, Madrid, medicamentos, Medicamentos de uso humano, Noviembre 2011, Nuevos medicamentos, Otra información de interés, Productos de higiene personal, Productos sanitarios, Rebif, salud, Sanidad, Uso humano.
Etiquetas: Actualización de la Información, Actualización sobre restricciones de uso, AEMPS, Agencia española de medicamentos y productos sanitarios, Agonistas dopaminérgicos ergóticos, Azacitidina, BINOCRIT, Cambios de especial interés sanitario en medicamentos ya autorizados, Cetuximab, Comité de Seguridad de Medicamentos de Uso Humano, CSMH, Darunavir, Epoetina alfa, Erbitux, Eszopiclona, Información dirigida a profesionales sanitarios, Información sobre seguridad, informe, Losartán potásico, LUNIVIA, Madrid, medicamentos, Mensual, Nuevas formulaciones de medicamentos ya autorizados, Nuevos medicamentos, octubre 2008, Orlistat, PEGASYS, Peginterferón alfa 2A, PREZISTA, Productos sanitarios, Resumen de la nota informativa, Rimonabant, salud, Sanidad, Terapia Hormonal en la Menopausia, Terapia hormonal sustitutiva, Uso humano, VIDAZA.
Etiquetas: Actualización de la información sobre presencia de contaminante en heparinas, Agencia española de medicamentos y productos sanitarios, Cambio en las condiciones de conservación, Cambios de especial interés sanitario en medicamentos ya autorizados, Cetuximab, Doribax, Erbitux, Gardasil, Madrid, Mayo 2008, medicamentos, Medicamentos de uso humano, Ministerio de Sanidad y Consumo, Monohidrato de doripenem, Neupro, Nota mensual, Nuevo servicio de suscripción a las listas de distribución de la Agencia, Nuevos medicamentos aprobados, Nuevos principios activos con dictamen positivo para su autorización, Productos sanitarios, Rotigotina, salud, Sanidad, Silgard, Solicitudes de ensayos clínicos electrónicas a la Agencia, Vacuna frente al Virus del Papiloma Humano.
Utilizamos cookies propias y de terceros para recopilar información que ayuda a optimizar su visita. Las cookies no se utilizan para recoger información de carácter personal. Usted puede permitir su uso o rechazarlo, también puede cambiar su configuración siempre que lo desee. Al continuar con la navegación entendemos que se acepta nuestra política de cookies.
x.gif)